Intellia Upgraded at Evercore ISI on Nex-Z Hypothesis (NTLA:NASDAQ)

Intellia upgraded at Evercore ISI on nex-z hypothesis (NTLA:NASDAQ)

Intellia Therapeutics (NTLA) stock jumps as Evercore ISI upgraded the company on a hypothesis behind a safety signal related to its nex-z gene therapy. Read more here.

Pharmalittle: We're reading about Moderna's flu shot, a death in a gene-editing trial in China, and more

Pharma news today includes: The Food and Drug Administration approved Moderna’s mRNA influenza vaccine for older adults.

Intellia says it has found a key clue to its gene editing safety issues

Intellia Therapeutics said it discovered a common link among the patients who faced the highest liver enzyme elevations after receiving its CRISPR gene editing treatment for ATTR amyloidosis. The gene editing ...